Finerenone
Brand name: Kerendia
Rank #175 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$89.5M
Total Cost
93,151
Total Claims
$89.5M
Total Cost
2,529
Prescribers
$961
Cost per Claim
12,377
Beneficiaries
137,116
30-Day Fills
$35K
Avg Cost/Provider
37
Avg Claims/Provider
Share of Medicare Part D Spending
0.03%
of total Medicare Part D spending
$89.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $89.5M total
🔎 Data Overview
Average cost of $7,232 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Finerenone
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Jeffrey Feldman | Nephrology | Union, NJ | 720 | $1.0M |
| 2 | Richard Dodd | Endocrinology | Asheville, NC | 768 | $761K |
| 3 | Ahmet Ergin | Endocrinology | Port St Lucie, FL | 425 | $573K |
| 4 | Yiling Huang | Internal Medicine | Elmhurst, NY | 523 | $466K |
| 5 | Ankush Gulati | Nephrology | Lehigh Acres, FL | 346 | $443K |
| 6 | Vlad Nusinovich | Internal Medicine | West Hollywood, CA | 626 | $425K |
| 7 | Enrique Griego | Family Practice | Mcallen, TX | 303 | $418K |
| 8 | David Whaley | Family Practice | Sumter, SC | 518 | $411K |
| 9 | Matin Sharafatkhah | Endocrinology | Brooklyn, NY | 545 | $405K |
| 10 | Sunny Melendez | Endocrinology | Torrance, CA | 353 | $390K |
| 11 | Michael Dao | Internal Medicine | Garden Grove, CA | 277 | $388K |
| 12 | Karla Menjivar | Nurse Practitioner | Los Angeles, CA | 525 | $379K |
| 13 | Luis Garcia-Mayol | Nephrology | Coral Gables, FL | 399 | $361K |
| 14 | Richard Chan | Nephrology | New York, NY | 376 | $349K |
| 15 | Eldrid Baez Matos | Nephrology | Dallas, TX | 290 | $342K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
| 174 | Mepolizumab (Nucala) | $90.1M | 20,798 |
| 175 | Finerenone (Kerendia) | $89.5M | 93,151 |
| 176 | Ixazomib Citrate (Ninlaro) | $89.0M | 6,901 |
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology